1-20 of 94
Jeffrey L Jorgensen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Mahesh Swaminathan, Koichi Takahashi, Zeev Estrov, Marina Y. Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado Valero, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A. Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 4635.
https://doi.org/10.1182/blood-2023-189711
Published: 2023
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Nitin Jain, Philip Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati, Koichi Takahashi, Mahesh Swaminathan, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan M. Kadia, Naveen Pemmaraju, Koji Sasaki, Divyam Bansal, Marina Y. Konopleva, Elias Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Wei Wang, Sa A. Wang, Jeffrey L. Jorgensen, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop M. Kantarjian, Susan M. O'Brien, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 3267.
https://doi.org/10.1182/blood-2023-188084
Published: 2023
Journal Articles

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Daniel Nguyen, Farhad Ravandi, Sa A. Wang, Jeffrey L. Jorgensen, Wei Wang, Kelly S. Chien, Guillermo Montalban-Bravo, Ghayas C. Issa, Abhishek Maiti, Yesid Alvarado Valero, Naval Daver, Courtney D. DiNardo, Elias Jabbour, Tapan M. Kadia, Naveen Pemmaraju, Musa Yilmaz, Jaehyun Lee, Pavan Bachireddy, Uday R. Popat, Guillermo Garcia-Manero, Hagop M. Kantarjian, Nicholas J. Short
Journal: Blood
Blood (2023) 142 (Supplement 1): 322.
https://doi.org/10.1182/blood-2023-190693
Published: 2023
Journal Articles

Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission

Elias J. Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey L Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney D DiNardo, Lucia Masarova, Tapan M. Kadia, Rebecca Garris, Farhad Ravandi, Hagop M Kantarjian
Journal: Blood
Blood blood.2023022330.
https://doi.org/10.1182/blood.2023022330
Published: 2023
Includes: Supplemental data
Journal Articles

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Fadi Haddad, Elias Jabbour, Nicholas Short, Nitin Jain, Emmanuel Almanza Huante, Koji Sasaki, Patrice Nasnas, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Marina Konopleva, Guillermo Garcia-Manero, Richard E Champlin, Tapan M. Kadia, Koichi Takahashi, Naval Daver, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Jovitta Jacob, Rebecca Garris, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 11698–11701.
https://doi.org/10.1182/blood-2022-170049
Published: 2022
Journal Articles

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Tareq Abuasab, Fadi Haddad, Shehab Fareed Mohamed, Jeffrey L. Jorgensen, Sa A Wang, Philip A. Thompson, Tapan M. Kadia, Yesid Alvarado, Sherry A. Pierce, Michael J. Keating, David McCue, Hagop Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 9385–9386.
https://doi.org/10.1182/blood-2022-165639
Published: 2022
Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Alexandre Bazinet, Tapan M. Kadia, Nicholas Short, Gautam Borthakur, Sa A Wang, Sanam Loghavi, Jeffrey L. Jorgensen, Keyur P. Patel, Courtney D. DiNardo, Naval Daver, Yesid Alvarado, Fadi Haddad, Sherry A. Pierce, Graciela M. Nogueras González, Abhishek Maiti, Michael Andreeff, Elias Jabbour, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 2267–2269.
https://doi.org/10.1182/blood-2022-162892
Published: 2022
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Marina Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 234–237.
https://doi.org/10.1182/blood-2022-170850
Published: 2022
Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Walid Macaron, Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Ghayas C. Issa, Naval Daver, Sa A Wang, Jeffrey L. Jorgensen, Keyur Patel, Sanam Loghavi, Marina Konopleva, Musa Yilmaz, Elias Jabbour, Abhishek Maiti, Hussein A Abbas, Elizabeth J Shpall, Uday R Popat, Gheath Alatrash, Sherry A. Pierce, Hagop Kantarjian, Nicholas Short
Journal: Blood
Blood (2022) 140 (Supplement 1): 543–545.
https://doi.org/10.1182/blood-2022-156955
Published: 2022
Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser, Sylvie D. Freeman, Gert J. Ossenkoppele, Francesco Buccisano, Christopher S. Hourigan, Lok Lam Ngai, Jesse M. Tettero, Costa Bachas, Constance Baer, Marie-Christine Béné, Veit Bücklein, Anna Czyz, Barbara Denys, Richard Dillon, Michaela Feuring-Buske, Monica L. Guzman, Torsten Haferlach, Lina Han, Julia K. Herzig, Jeffrey L. Jorgensen, Wolfgang Kern, Marina Y. Konopleva, Francis Lacombe, Marta Libura, Agata Majchrzak, Luca Maurillo, Yishai Ofran, Jan Philippe, Adriana Plesa, Claude Preudhomme, Farhad Ravandi, Christophe Roumier, Marion Subklewe, Felicitas Thol, Arjan A. van de Loosdrecht, Bert A. van der Reijden, Adriano Venditti, Agnieszka Wierzbowska, Peter J. M. Valk, Brent L. Wood, Roland B. Walter, Christian Thiede, Konstanze Döhner, Gail J. Roboz, Jacqueline Cloos
Journal: Blood
Blood (2021) 138 (26): 2753–2767.
https://doi.org/10.1182/blood.2021013626
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Sangeetha Venugopal, Nicholas J. Short, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Sherry A. Pierce, Sanam Loghavi, Keyur P. Patel, Ghayas C. Issa, Hagop Kantarjian, Sa A Wang, Farhad Ravandi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2374.
https://doi.org/10.1182/blood-2021-154105
Published: 2021
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Fadi Haddad, Hagop Kantarjian, Nicholas J. Short, Koji Sasaki, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Nitin Jain, Marina Konopleva, Guillermo Garcia-Manero, Richard E. Champlin, Tapan M. Kadia, Koichi Takahashi, Naval Daver, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Jovitta Jacob, Rebecca Garris, Susan M. O'Brien, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 3363.
https://doi.org/10.1182/blood-2021-154155
Published: 2021
Journal Articles

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Nitin Jain, Tapan M. Kadia, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Yesid Alvarado, Jan A. Burger, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Naveen Pemmaraju, Guillermo Garcia-Manero, William G. Wierda, Steven M. Kornblau, Jovitta Jacob, Monica Kwari, Caitlin R. Rausch, Christopher Loiselle, Anna Milton, Juan Rivera, Rebecca Garris, Susan M. O'Brien, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 3400.
https://doi.org/10.1182/blood-2021-154074
Published: 2021
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Koji Sasaki, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias J. Jabbour, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey L. Jorgensen, Sa A Wang, Naveen Garg, Xuemei Wang, Chongjuan Wei, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 3720.
https://doi.org/10.1182/blood-2021-154454
Published: 2021
Journal Articles

Oligoblastic (<20%) Myeloid Neoplasms with KMT2A ( MLL ) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML

Sergej Konoplev, Guilin Tang, Xiaoqiong Wang, Wei Wang, Beenu Thakral, Jie Xu, Sherry A. Pierce, Jeffrey L. Jorgensen, Farhad Ravandi, Ghayas C. Issa, Olga Pozdnyakova, Sa A Wang, Robert P. Hasserjian
Journal: Blood
Blood (2021) 138 (Supplement 1): 793.
https://doi.org/10.1182/blood-2021-153749
Published: 2021
Journal Articles

Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Philip A. Thompson, Alessandra Ferrajoli, Tapan M. Kadia, Nitin Jain, Yesid Alvarado, Musa Yilmaz, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Steven M. Kornblau, Marina Konopleva, Guillermo Garcia-Manero, Rebecca Garris, Heather M Schroeder, Anna Milton, Juan Rivera, Glenda Banks, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 1233.
https://doi.org/10.1182/blood-2021-154022
Published: 2021
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Naval Daver, MD, Hind Rafei, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Maria R Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-139896
Published: 2020
Journal Articles

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Hind Rafei, MD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Maria Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-140037
Published: 2020
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Yesid Alvarado, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Serena Chew, PharmD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Maria Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-143386
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-143286
Published: 2020